MENU

New Information About Head and Neck Cancer Outlined in Molecular Determinants of Head and Neck Cancer, 2nd Edition

July 11, 2018

PHILADELPHIA (July 11, 2018) – Fox Chase Cancer Center is pleased to announce the publication of Molecular Determinants of Head and Neck Cancer, 2nd Edition, edited by Erica Golemis, PhD, deputy chief science officer at Fox Chase Cancer Center, and Barbara Burtness, MD, Disease Aligned Research Team Leader of the Head and Neck Cancers Program at Yale Cancer Center.

This new edition informs readers of significant advances in the understanding of this disease and the new therapies that have become available, with a focus on novel drug targets to improve the outcomes of head and neck squamous cell carcinomas (HNSCC). HNSCCs arise in the oral cavity, pharynx, and larynx; approximately 600,000 new cases will be diagnosed worldwide in 2018.

The book specifically addresses the biology and treatment of different subtypes of HNSCC, including the rapidly growing class of human papillomavirus (HPV) – driven HNSCC. Along with Golemis and Burtness, several current and former Fox Chase faculty members contributed to this book, including  Jeffrey Liu, Camille RaginSuraj Peri, Andrew J. Andrews, Ranee Mehra, and Ilya G. Serebriiskii.

“In the four years, since the original book was published, we have seen considerable advances in understanding disease mechanisms, and developing new treatments, including promising new immunotherapies,” said Golemis. “The key to success in treating HNSCC comes from our ability to translate bench research into clinical trials, which is emphasized in this updated edition.”

The second edition is available for purchase now.

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. 
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase